Prasugrel Monotherapy After Percutaneous Coronary Intervention With Biodegradable-Polymer Platinum-Chromium Everolimus Eluting Stent for Japanese Patients With Chronic Coronary Syndrome (ASET-JAPAN)

• Published in: Circulation Journal 2023/05/25, Vol.87(6), pp.857-865
• Main Authors: Muramatsu, Takashi, Masuda, Shinichiro, Kotoku, Nozomi, Kozuma, Ken, Kawashima, Hideyuki, Ishibashi, Yuki, Nakazawa, Gaku, Takahashi, Kuniaki, Okamura, Takayuki, Miyazaki, Yosuke, Tateishi, Hiroki, Nakamura, Masato, Kogame, Norihiro, Asano, Taku, Nakatani, Shimpei, Morino, Yoshihiro, Katagiri, Yuki, Ninomiya, Kai, Kageyama, Shigetaka, Takahashi, Hiroshi, Garg, Scot, Tu, Shengxian, Tanabe, Kengo, Ozaki, Yukio, Serruys, Patrick W., Onuma, Yoshinobu
• Format: Article
• Language: English
• Subjects: Antiplatelet monotherapy; Aspirin; Coronary artery disease; Drug-eluting stent; Drug-Eluting Stents; East Asian People; Everolimus; Hemorrhage; Humans; Japan; Percutaneous coronary intervention; Percutaneous Coronary Intervention - methods; Pilot Projects; Platinum; Polymers; Prasugrel; Prasugrel Hydrochloride - therapeutic use; Prospective Studies
• ISSN: 1346-9843; 1347-4820; 1347-4820
• DOI: 10.1253/circj.CJ-23-0051

Background: P2Y12 inhibitor monotherapy without aspirin immediately after percutaneous coronary intervention (PCI) has not been tested in East Asian patients, so in this study we aimed to assess the safety and feasibility of reduced dose (3.75 mg/day) prasugrel monotherapy in Japanese patients presenting with chronic coronary syndrome (CCS).Methods and Results: ASET-JAPAN is a prospective, multicenter, single-arm pilot study that completed enrolment of 206 patients from 12 Japanese centers in September 2022. Patients with native de-novo coronary lesions and a SYNTAX score